Podcasts about Nature Medicine

Circulating tumor DNA (ctDNA), a minimally invasive blood-based biomarker, has emerged as one of the most promising advances in cancer surveillance. Today, we will explore how ctDNA is transforming the management of colorectal cancer and anal squamous cell cancer across the disease continuum—from risk stratification and adjuvant therapy decision-making to surveillance and early detection of recurrence. Through landmark clinical trials, real-world applications, and emerging research, we will examine how ctDNA is helping move cancer care closer to the goal of truly personalized medicine.Hosts: ·       Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center·       Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian·       Dr. Philip Bauer, Assistant Professor of Surgery, Division of Colon and Rectal Surgery, The Ohio State University Wexner Medical Center, Arthur G. James Cancer Hospital·       Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer CenterGuests:Dr. Paul Romessor ·      Director of Colorectal and Anal Cancer, Department of Radiation Oncology·      Associate Attending Radiation OncologistMemorial Sloan Kettering Cancer CenterDr. Jeanne Tie ·      Medical Oncologist | Lower GI Unit ·      Lower GI Research Lead ·      Chair | Lower GI Working Party | GI Cancer TrialsPeter MacCallum Cancer Centre Dr. Takayuki Yoshino·      Professor, Global Center of Research Excellence for Advanced Medicine (G-CORE),Keio University School of Medicine·      Executive Advisor to Hospital East Director·      Director, Department of Global Oncology·      Chief, Department of Gastrointestinal OncologyNational Cancer Center Hospital EastLearning Objectives:·      Describe the biological basis and clinical applications of circulating tumor DNA (ctDNA) as a biomarker of minimal residual disease (MRD) in colorectal cancer.·      Interpret the prognostic significance of postoperative and longitudinal ctDNA testing and its role in predicting recurrence risk across stages of colorectal cancer.·      Evaluate evidence from landmark clinical trials, including DYNAMIC and GALAXY, supporting ctDNA-guided treatment de-escalation and escalation strategies in colorectal cancer.·      Discuss emerging applications of ctDNA monitoring in personalized cancer care, including surveillance, treatment response assessment, and future clinical trial directions. References:·      Ando, K. et al. (2026). Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort Study. Annals of Surgery. https://pubmed.ncbi.nlm.nih.gov/39854721/ (Note: If direct access is limited, the article is available via PMC: PMC12695342)·      Romesser, P. B. et al. (2026). Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/38347209/·      Tie, J. et al. (2025). Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/39943485/·      Tie, J. et al. (2025). Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/39974258/Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Avanços no tratamento de Alzheimer, nova vacina da Anvisa contra a gripe e IA na medicina (NeroVFM).O avanço clínico do medicamento experimental Diranersen, desenvolvido pela Biogen, demonstrou capacidade de atenuar a perda de funções cognitivas ao atuar diretamente sobre marcadores proteicos celulares em estudo de fase 2. A Anvisa aprovou o imunizante trivalente inativado Fluprevli, indicado para a proteção contra cepas sazonais em adultos e crianças a partir dos seis meses de idade. Por fim, trazemos no Radar o estudo publicado na Nature Medicine sobre o NeuroVFM, um modelo de IA na medicina treinado em milhões de exames de tomografia e ressonância para refinar a precisão e a triagem em neuroimagem clínica. O Afya News apresenta notícias da medicina com informação confiável e atualizada no seu tempo. Criado pela Afya Educação Médica, o maior hub de educação e soluções para a prática médica do Brasil, nosso propósito é transformar a saúde junto com quem tem a medicina como vocação.Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/16-07-2026

Send us Fan MailAfter a disappointing IVF retrieval, it is tempting to change everything. But does a new protocol actually explain a better next cycle—or is biology doing some of the talking?In this episode, Dr. Mark Amols explains why IVF protocols absolutely matter, but why there is no single “perfect” protocol that can guarantee a certain number of eggs or mature eggs. Using the analogy of an Olympic runner and the right running shoes, he breaks down the physician's role: optimize the medication plan, timing, trigger, and safety—without pretending we can fully control ovarian biology.Dr. Amols reviews a 2026 Fertility and Sterility study of 801 consecutive IVF cycle pairs showing substantial cycle-to-cycle variation even when patients used the same stimulation protocol and dose. He also discusses why mature eggs matter more than total egg count, when a protocol change is purposeful, and why retrieval and lab workflow can influence the final egg number too.If your last IVF cycle did not go as hoped, this episode will help you ask the better question: not “What can we change?” but “What did we learn, and what are we trying to improve?”Referenced studies: Hochberg et al., Fertility and Sterility (2026); Mutlu et al., Nature Medicine (2026).Thanks for tuning in to another episode of 'Taco Bout Fertility Tuesday' with Dr. Mark Amols. If you found this episode insightful, please share it with friends and family who might benefit from our discussion. Remember, your feedback is invaluable to us – leave us a review on Apple Podcasts, Spotify, or your preferred listening platform.Stay connected with us for updates and fertility tips – follow us on Facebook. For more resources and information, visit our website at www.NewDirectionFertility.com.Have a question or a topic you'd like us to cover? We'd love to hear from you! Reach out to us at TBFT@NewDirectionFertility.com.Join us next Tuesday for more discussions on fertility, where we blend medical expertise with a touch of humor to make complex topics accessible and engaging. Until then, keep the conversation going and remember: understanding your fertility is a journey we're on together.

Academic Summary: A sweeping cohort study spanning over 164,000 individuals across the US and UK confirms that recent generations are aging biologically much faster than their predecessors. The data reveals a staggering generational acceleration: people born between 1965 and 1974 exhibit a 23% higher biological "age gap" than those born in the early 1950s, while individuals born in the 1990s demonstrate an astonishing 92% higher age gap compared to those born in the late 1960s. This compounding cellular wear-and-tear—driven by modern environmental exposures, ultra-processed diets, and sedentary behavior—directly correlates to the alarming rise in early-onset cancers. Specifically, every standard deviation increase in biological aging raises the risk of early-onset lung cancer by 57% and colorectal cancer by 14%. By quantifying exactly how much faster newer generations are aging, this research provides a critical roadmap to deploy targeted lifestyle interventions and intercept disease before it begins. #BiologicalAge #CancerPrevention #GenerationalHealth #Healthspan #PhenoAge #TheCatalyst #LongevityScience #FutureOfMedicine #EpigeneticsFormal Citation:Tian R, Zong X, Ren D, et al. Biological aging and generational shifts in early-onset cancer risk. Nature Medicine. 2026. doi:10.1038/s41591-026-04448-w Medical & Legal Disclaimer:This content is for educational and informational purposes only and does not constitute medical advice. Always consult a healthcare professional before making any health decisions. NARRATOR: Ralph Turchiano. ANALYSIS: Claude / GeminiNON-MONETIZED: The Catalyst is a non-monetized, knowledge-sharing platform.

Randomized evidence suggests that routinely used mucoactive therapies may no longer have a role in mechanically ventilated ICU patients, while a large comparative effectiveness study indicates GLP-1 receptor agonists may offer superior cardiovascular and atrial fibrillation outcomes compared with SGLT2 inhibitors in patients with both AF and type 2 diabetes. We also highlight a promising blood-based RNA biomarker panel that may predict Alzheimer's symptom onset several years before cognitive decline, potentially improving patient selection for emerging disease-modifying therapies.

I received a podcast review that basically said because a guest talked about chronic inflammation it was a "MAHA podcast." So I decided to go straight to one of the top inflammation researchers in the world and ask him directly: is chronic inflammation actually real, or is it pseudoscience?  My guest is Dr. David Furman, the Director of Stanford Medicine's 1000 Immunomes Project (the largest longitudinal study on aging and the immune system in the world) and an Associate Professor at the Buck Institute for Research on Aging, and his answer might surprise you. We play a game of Myth or Fact and bust some of the biggest inflammation claims all over the internet, from gluten and dairy to seed oils, and microplastics. We also get into how to actually test whether you're inflamed, the surprising link between chronic stress, depression, and your immune system, why your coffee habit might be doing you a favor, and exactly what to do about all of it if you have no money to spend.

Una nueva inteligencia artificial de Harvard quiere ayudar a responder una pregunta enorme en medicina: ¿qué pacientes con cáncer van a beneficiarse realmente de la inmunoterapia?El modelo se llama COMPASS. Fue presentado en Nature Medicine y analiza la actividad genética de tumores para estimar si una persona tiene más probabilidad de responder a medicamentos conocidos como inhibidores de puntos de control inmunitario.Dicho más simple: algunos tumores logran esconderse del sistema inmune. Estos medicamentos intentan quitarles ese disfraz. En algunas personas funcionan muy bien. En otras, no funcionan. Y ahí está el problema.Según Harvard Medical School, COMPASS superó en un 8,5 por ciento a los mejores métodos existentes para predecir respuesta.Bibliografía Clinical Trial Vanguardhttps://www.clinicaltrialvanguard.com/article/article-deep-dive/harvards-compass-model-just-made-immunotherapy-trial-design-more-complicated/Nature Medicine (artículo científico original)https://www.nature.com/articles/s41591-026-04502-7Harvard Medical Schoolhttps://hms.harvard.edu/news/ai-tool-improves-prediction-who-will-respond-cancer-immunotherapy-drugsThe Engineerhttps://www.theengineer.co.uk/content/news/harvard-ai-model-predicts-cancer-immunotherapy-responseMedical Xpresshttps://medicalxpress.com/news/2026-07-ai-tool-cancer-immunotherapy-drugs.htmlPubMed (resumen indexado del estudio)https://pubmed.ncbi.nlm.nih.gov/40385399/Conviértete en un supporter de este podcast: https://www.spreaker.com/podcast/flash-diario-de-el-siglo-21-es-hoy--5835407/support.⚡️

Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/02-07-2026Nesta quinta-feira, o boletim analisa as marcas biológicas duradouras de tratamentos comuns, novas recomendações regulatórias na neurologia e o impacto histórico de imunizantes consagrados. Abordamos um estudo da Nature Medicine demonstrando que o uso de certos antimicrobianos pode gerar alterações na composição das bactérias intestinais por até oito anos. Detalhamos a recomendação da agência europeia (EMA) para a aprovação do fármaco Hopledo®, uma nova formulação de levodopa voltada para o manejo de flutuações motoras moderadas a graves. Por fim, no Radar, celebramos o Dia da Vacina BCG, reforçando a importância de resgatar altas coberturas vacinais na infância contra evoluções clínicas graves. Afya News. Informação médica confiável e atualizada no seu tempo.

Estudo publicado na Nature Medicine concluiu que as gerações mais novas estão a envelhecer mais rápido. O envelhecimento sistémico aumenta o risco de cancro em 8%See omnystudio.com/listener for privacy information.

Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/26-06-2026Nesta sexta-feira, o boletim analisa um mapeamento metabólico na oncologia, as primeiras diretrizes unificadas da OMS para patologias emergentes e o desempenho de ferramentas digitais. Abordamos um estudo da Nature que identificou biomarcadores plasmáticos (como a histidina) capazes de prever a taxa de resposta dos pacientes aos tratamentos de imunoterapia. Detalhamos o novo documento global da OMS que padroniza o manejo clínico e o suporte intensivo para infecções raras por filovírus, visando mitigar evoluções clínicas graves. Por fim, discutimos no Radar uma análise da Nature Medicine demonstrando que modelos de inteligência artificial generalistas superaram plataformas médicas especializadas no suporte à tomada de decisão. Afya News. Informação médica confiável e atualizada no seu tempo.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of impactful developments shaping the future of medical innovation and patient care. The landscape of pharmaceutical and biotech industries is currently experiencing notable shifts driven by scientific advancements, regulatory updates, and strategic collaborations. One of the more controversial events involves the retraction of a high-profile study in Nature Medicine. This study initially suggested that the timing of PD-1 inhibitor administration had significant impacts on survival rates for non-small cell lung cancer patients. Early-day administration was linked to improved outcomes compared to later in the day. However, after a four-month investigation, concerns over methodological validity led to its retraction. This incident serves as a stark reminder of the necessity for rigorous peer review and transparency in clinical research, which are essential for influencing treatment protocols effectively. In industry news, Eli Lilly has entered into a major $1.9 billion partnership with Abbisko Therapeutics to harness Abbisko's drug discovery capabilities, particularly in oncology. This collaboration highlights an increasing trend where Western pharmaceutical companies team up with Asian biotech firms to accelerate drug development and tap into innovative therapeutic platforms. Eli Lilly is also recalibrating its strategy for launching its oral obesity treatment, Foundayo, in Europe, as it navigates the complexities introduced by the Most Favored Nation pricing agreement with the U.S. This underscores a broader challenge within the industry: balancing pricing regulations with expanding access through digital health channels like telehealth. ADC Therapeutics is taking steps to address safety concerns surrounding its antibody-drug conjugate, Zynlonta, by reducing its workforce by 17%. This strategic realignment demonstrates the delicate balance companies must maintain between advancing promising therapies and ensuring patient safety through vigilant clinical oversight. On the regulatory front, Incyte's decision to drop its lawsuit against CMS over drug classification issues involving its JAK inhibitor Opzelura highlights ongoing negotiations between pharmaceutical companies and regulatory bodies. These classifications have direct implications for market access and reimbursement strategies. Shifting focus to infrastructure, Advancell's move to establish its U.S. headquarters near Boston for radiopharmaceutical production underscores an emphasis on localizing drug manufacturing facilities to enhance supply chain resilience. This decision aligns with broader efforts to support domestic clinical trials for innovative therapies targeting prostate cancer. In terms of technological innovation, Novartis has invested $105 million upfront in Antares Therapeutics to target historically undruggable cancer proteins through small molecule development. This move reflects an industry-wide push towards exploiting cutting-edge technologies like AI-driven drug discovery to meet unmet medical needs in oncology. Precision medicine continues to gain traction, exemplified by Abbott's partnership with AlzPath to develop blood-based diagnostic tests for Alzheimer's disease. Collaborations such as these are pivotal in enhancing early diagnosis and personalized treatment approaches for neurodegenerative disorders. Meanwhile, the industry's financial dynamics continue to evolve with significant fundraising activities. Serapha Bio's public debut through a reverse merger with Boundless Bio raised $230 million, highlighting a growing trend of utilizing reverse mergers as a pathway to public markets. This financial boost comes alongside their licensing of a gene editing technology from China, underscoring the global nature of biotech collaborations. In oncology, Eli Lilly's extended partnership with Abbisko Therapeutics underscores the ongoing commitment to precision medicine, aiming to harness small molecule innovations targeting specific cancer pathways. Concurrently, the European Medicines Agency approved Astellas' Padcev combined with Merck & Co.'s Keytruda for muscle-invasive bladder cancer treatment based on promising Phase 3 results. Ophthalmology research is also seeing substantial investment with Ollin Biosciences raising $330 million in Series B funding aimed at developing therapies that challenge existing treatments like Vabysmo for eye diseases. Such investments indicate strong confidence in novel therapies that could redefine standards in treating conditions like wet age-related macular degeneration. In conclusion, these developments reflect a vibrant biotech and pharma landscape characterized by strategic partnerships, innovative financing mechanisms, and regulatory milestones that collectively drive forward scientific progress and enhance therapeutic options available worldwide. As these sectors continue to evolve, integrating cutting-edge technologies like gene editing and precision oncology will be pivotal in shaping healthcare delivery's future trajectory while improving patient outcomes globally.Support the show

Nová studie v prestižním časopise Nature Medicine ukázala něco, co vědce samotné překvapilo: stopa po antibioticích zůstává ve střevním mikrobiomu až osm let. Přitom se s nimi nadměrně plýtvá: každé čtvrté se předepisuje zbytečně. I kvůli tomu se bakterie stávají odolnými a mnohé léky na ně už nefungují. Například některé druhy manažerských – tedy třídenních – antibiotik, která se dávají na angínu. Na ně je odolná už každá pátá bakterie. Mikrobiolog Jakub Hurych vysvětluje, která antibiotika škodí mikrobiomu nejvíc, proč zelený hlen není důkaz bakteriální infekce nebo co říká věda o probioticích. Předplatitelé se dozvědí všechny fígle o tom, jak mikrobiom po léčbě co nejrychleji obnovit, jakých třicet potravin pomáhá nejvíce a jaké další léky mohou střeva negativně ovlivnit.

Apply for coaching

Dr Amelia Harry is an experienced Advanced Accredited Practising Dietitian, Accredited Nutritionist, and plastics, diet & human health researcher. In this chat, we discuss the latest publication (in Nature Medicine) that Dr Amelia co-authored on the results of the Plastic Exposure Reduction Transforms Health (PERTH) Trial - which assessed phthalates and bisphenols in humans and what impact a change in diet had. We discuss the methodology, results (it's good news !!) and how you can minimise plastic ingestion in your own life (and why you should).Useful links:Dr Amelia on LinkedIn (here)eatsustainably.com.auJournal paper, Low-plastic diet and urinary levels of plastic-associated phthalates and bisphenols: the randomized controlled PERTH Trial (here) Hosted on Acast. See acast.com/privacy for more information.

Doctor Mau Informa ®️ #drmauinforma Durante medio siglo, la endocrinología consideró al glucagón como el "villano" del metabolismo: la hormona responsable de subir el azúcar en la sangre. Sin embargo, ¿qué pasaría si pudiéramos domesticar a este villano para activar la quema extrema de grasa de forma segura. En este episodio de Doctor Mau Informa, analizamos la fascinante evolución científica que nos llevó desde tumores pancreáticos hasta el desarrollo del Retatrutide, un revolucionario fármaco "triple agonista". Descubre cómo la ciencia logró combinar tres señales hormonales (Glucagón, GLP-1 y GIP) en una sola inyección semanal para alcanzar resultados de pérdida de peso metabólica que antes solo le pertenecían al bisturí de la cirugía bariátrica. En este episodio aprenderás: → La balanza de la pérdida de peso: Por qué los medicamentos anteriores solo te quitaban el hambre, y cómo la nueva generación también acelera tu gasto energético. → El secreto del Glucagón: Cómo esta hormona del ayuno saca la grasa del hígado y eleva el metabolismo. → La evolución del GLP-1: El papel protector de la insulina natural para contrarrestar el azúcar y permitir una pérdida de peso segura. → Cirugía vs. Fármacos: Por qué los resultados de los nuevos tratamientos crónicos están cambiando el paradigma médico para siempre. → La realidad clínica: Efectos secundarios, la importancia de la titulación médica y por qué esto no es una "dieta milagro".

“I didn't know I enjoyed thinking so much,” says science writer Roxanne Khamsi when asked what surprised her most about writing her first book Beyond Inheritance. “I thought I enjoyed interviewing people and reading research papers and the process of finding the right verb in a sentence. What's hard for me is once I get into that thinking space, I can't let go of it.” In this episode we talk about how she made the leap from writing articles to writing a book—and why they are so different. We talk about creating an arc for a book of essays, what to do when the structure for your book isn't working, letting go of a project once its over, meeting our self critic, the role of obsession in writing a book, the art of going for “the big idea” and how to carry that in a nonfiction book, how writing reflects the author's personality.Roxanne Khamsi is the author of Beyond Inheritance: Our Ever-Mutating Cells and a New Understanding of Health and a contributing writer at The Atlantic. Her articles on genetics have appeared in a wide range of publications, including The New York Times, Scientific American, Nature magazine and Wired. Roxanne served as chief news editor for the international research journal Nature Medicine for more than a decade. She is based in Montreal.Author photos credit: Brian Friedman This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit emergingform.substack.com/subscribe

Mikroplastik ist überall. Im Wasser. In Lebensmitteln. In der Luft. Auf dem Boden. Und ja, inzwischen wird es auch im menschlichen Körper nachgewiesen. Aber was heißt das jetzt konkret? Müssen wir ab morgen nur noch aus Glas trinken? Sind Plastikschneidebretter ein echtes Problem? Ist die Mikrowelle gefährlich? Essen wir wirklich jede Woche eine Kreditkarte Plastik? Und was bedeutet es, wenn Studien Mikroplastik im Gehirn oder sogar in der Plazenta finden? In dieser Folge spreche ich mit Prof. Dr. Christian Laforsch, Biologe an der Universität Bayreuth und Sprecher des Sonderforschungsbereichs Mikroplastik. Er forscht seit vielen Jahren dazu, wie Mikroplastik entsteht, wie es sich in der Umwelt verbreitet und welche möglichen Folgen es für Ökosysteme und Gesundheit haben kann.

Myoscience GlyNAC (20% off, exclusive to this community): https://bit.ly/4auv3xW  Pre-order Keto Flex Revised and get free bonuses at: https://bit.ly/4wKG1sM    A 2026 randomized controlled trial called the PERTH trial found that people reduced plastic-related chemicals in their bodies by up to 60% in just seven days by swapping their food, kitchenware, and personal care products. The research behind this is not fringe. A study in the New England Journal of Medicine found microplastics embedded in arterial plaque in over half of 257 surgical patients. Those patients had a 4.5 times higher risk of heart attack, stroke, or death. A 2025 Nature Medicine study found the average human brain now holds roughly a spoonful of microplastic particles, up 50% in just eight years. In dementia brains, the concentration was ten times higher. In this episode, Ben walks through exactly where exposure comes from, what these plastics are doing to your hormones, your metabolism, your inflammation, and your brain, and the simple five-step protocol you can start today. Key takeaways: A single liter of bottled water contains around 240,000 microplastic particles on average One plastic teabag releases 11.6 billion plastic particles into a single cup of hot water BPA mimics estrogen at receptor sites, disrupting testosterone in men and fertility in women Your body stores these chemicals in fat cells through a pathway called PPAR gamma, creating new fat cells if it runs out of room Glutathione is the master molecule your liver uses to neutralize and eliminate these toxins, and modern life depletes it constantly NAC supplies the cysteine your liver needs to produce glutathione internally The five-step protocol: stop heating plastic, filter your water, eat real food, sweat daily, prioritize fiber and hydration Find All The Ben Azadi Show Sponsorship Deals ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.ketokamp.com/sponsorship-deals Learn more about your ad choices. Visit megaphone.fm/adchoices

What if there was literally a plastic spoon's worth of microplastics sitting inside your brain right now? In this jaw-dropping and deeply urgent solo episode, Darin Olien breaks down the newest science on microplastics, nanoplastics, brain accumulation, neuroinflammation, endocrine disruption, and the rapidly escalating contamination of the human body. Referencing groundbreaking new research published in Nature Medicine and newly launched U.S. government initiatives, Darin exposes how plastics are no longer just an environmental issue—they are now a human biology issue. From nanoplastics crossing the blood-brain barrier to endocrine-disrupting chemicals like BPA, PFAS, and phthalates accumulating in tissues, placentas, and testes, this episode explores the shocking implications of modern plastic exposure—and, more importantly, what practical steps you can take immediately to reduce your risk.     What You'll Learn The shocking new study finding microplastics in 100% of healthy human brains Why the average brain may now contain roughly a plastic spoon's worth of plastic How nanoplastics cross the blood-brain barrier The alarming connection between microplastics and dementia research Why plastics are not biologically inert substances The endocrine-disrupting chemicals hitchhiking on microplastics How bottled water, tea bags, coffee pods, and heated plastics dramatically increase exposure The role of PFAS, BPA, phthalates, and flame retardants in human health decline Why reverse osmosis filtration is one of the most effective protective tools Practical ways to reduce microplastic exposure immediately     Chapters 00:00:03 – Welcome to SuperLife 00:00:33 – Sponsor: Alkemis wellness paint and indoor air toxicity 00:00:57 – Conventional paints, endocrine disruptors, and off-gassing chemicals 00:01:24 – VOC-free mineral paints and PFAS-free home environments 00:01:55 – Fire resistance, sustainability, and Cradle to Cradle certification 00:02:53 – Why the products surrounding us matter biologically 00:03:23 – New study finds microplastics in 100% of healthy human brains 00:03:44 – The U.S. government launches a $144 million microplastics initiative 00:03:52 – Visualizing a plastic spoon's worth of plastic in the brain 00:04:22 – The Nature Medicine findings explained 00:04:40 – Dementia brains containing dramatically more plastic accumulation 00:04:47 – Why this study is not "internet noise" 00:05:07 – Dr. Matthew Campen and the University of New Mexico research 00:05:15 – The STOMP program: Systemic Targeting of Microplastics 00:05:45 – From environmental issue to "inside your body" crisis 00:06:01 – What listeners will learn and actionable solutions 00:06:21 – Breaking down the Campen study in detail 00:06:38 – Gas chromatography mass spectrometry analysis explained 00:06:50 – Roughly seven grams of plastic found in average brains 00:07:09 – Brain tissue containing more plastic than liver or kidneys 00:07:21 – Dementia brains showing 10x more plastic concentration 00:07:28 – Nanoplastics crossing the blood-brain barrier 00:07:42 – The alarming acceleration of accumulation rates 00:08:03 – Healthy brains vs diseased brains and microplastic prevalence 00:08:24 – The unanswered question: dose and biological effect 00:08:40 – Correlation vs causation and scientific uncertainty 00:09:06 – Why the trend itself is deeply concerning 00:09:23 – Plastic accumulation in blood vessel walls and immune cells 00:09:46 – Chronic neuroinflammation and cognitive decline 00:09:56 – Plastics carrying phthalates, BPA, PFAS, and flame retardants 00:10:08 – Endocrine disruption and hormone interference 00:10:19 – Plastics found in placentas and testes 00:10:31 – "Structural pollution of the human body" 00:10:52 – The plastic industry externalizing costs onto humanity 00:10:58 – Practical steps listeners can take immediately 00:11:02 – Why bottled water may be a major source of nanoplastics 00:11:28 – Reverse osmosis filtration and reducing exposure 00:11:46 – AquaTru systems and affordable filtration solutions 00:12:09 – Sponsor: Shakeology and nutrient density 00:13:58 – Stop heating food in plastic immediately 00:14:17 – Heat dramatically increasing microplastic transfer into food 00:14:31 – Switching to glass, stainless steel, and ceramic containers 00:14:50 – Dangerous recycling codes and plastic leaching 00:15:13 – The hidden plastic problem inside tea bags 00:15:27 – One tea bag releasing billions of microplastics into tea 00:15:50 – Why Darin says to ditch plastic tea bags completely 00:16:02 – Loose leaf tea and stainless steel infusers 00:16:14 – Coffee pod machines and heated plastics under pressure 00:16:26 – Safer coffee alternatives: French press and pour-over 00:16:38 – Fiber helping bind and eliminate particulate matter 00:17:00 – Sweating, exercise, and toxin mobilization 00:17:22 – Polyphenols and antioxidant-rich foods 00:17:42 – Broccoli sprouts, sulforaphane, and glutathione support 00:18:24 – Omega-3s and reducing neuroinflammation 00:18:34 – The plastic industry's "safe and recyclable" narrative 00:18:58 – Comparing plastics to tobacco and PFAS deception 00:19:16 – Disposable convenience culture and "fatal conveniences" 00:19:45 – The simplest immediate change: replacing tea bags 00:20:10 – Taking sovereignty back through everyday choices 00:20:34 – Patreon deep dives and continuing the conversation 00:20:53 – "Your body is not a landfill" 00:21:08 – Why small daily choices compound biologically 00:21:22 – Final reflections and closing thoughts     Thank You to Our Sponsors Shakeology: Get 15% off with code DARINO1BODI at Shakeology.com. Alkemis: Go to https://alkemispaint.com/ and use code DARIN10 for 10% off your order.     Join the SuperLife Patreon: This is where Darin now shares the deeper work: - weekly voice notes - ingredient trackers - wellness challenges - extended conversations - community accountability - sovereignty practices Join now for only $7.49/month at https://patreon.com/darinolien     Connect with Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com New Show: Roadmap to Happiness     Key Takeaway "Microplastics are no longer just floating in oceans or polluting landfills—they are accumulating inside human beings. Inside our brains. Inside our blood vessels. Inside unborn children. But while the scale of the problem is staggering, the solution begins with everyday choices. What you drink from. What you heat your food in. What you filter. What you buy. Your body is not a landfill—and reclaiming your health starts with refusing to treat it like one."     Bibliography/Sources Primary Scientific Studies Bornstein, S. R., et al. (2025). Therapeutic apheresis: A promising method to remove microplastics? Brain Medicine . https://pmc.ncbi.nlm.nih.gov/articles/PMC12162106/ Campen, M., et al. (2025). Bioaccumulation of microplastics in decedent human brains. Nature Medicine . https://pmc.ncbi.nlm.nih.gov/articles/PMC11100893/ Campen, M., et al. (2026). Microplastics in 100% of healthy brain samples (2026 Update) . https://hsc.unm.edu/news/2024/05/microplastics-accumulate-in-brain.html Hernandez, L. M., et al. (2019). Plastic teabags release billions of microparticles and nanoparticles into tea. Environmental Science & Technology, 53(21), 12300–12310 . https://pubs.acs.org/doi/10.1021/acs.est.9b02540 Government & University Announcements Advanced Research Projects Agency for Health (ARPA-H). (2026, April 2). STOMP program launch . https://arpa-h.gov/explore-funding/programs/stomp U.S. Department of Health and Human Services (HHS). (2026, April 2). HHS press release on STOMP . https://arpa-h.gov/explore-funding/programs/stomp University of New Mexico Health Sciences Center. (n.d.). UNM HSC announcement - Microplastics in human brains . https://hsc.unm.edu/news/2024/05/microplastics-accumulate-in-brain.html Health & News Resources EurekAlert! (n.d.). Micronanoplastics found in artery-clogging plaque in the neck . https://www.eurekalert.org/news-releases/1080866 NYU Langone Health. (n.d.). 7 ways to reduce your exposure to microplastics . https://nyulangone.org/news/7-ways-reduce-your-exposure-microplastics

Jonathan Dickinson is the co-founder and CEO of Ambio Life Sciences, one of the world's leading ibogaine clinics. He's spent more than fifteen years on this — apprenticing in Tijuana clinics, running the Global Ibogaine Therapy Alliance, and writing the field's first clinical safety guidelines. He's a Mexico-licensed psychologist. He holds the only active export license for iboga root and led the first Nagoya-compliant export out of Gabon, where he was initiated into two Bwiti traditions. His team co-authored the Stanford study in Nature Medicine on ibogaine and veteran traumatic brain injury. Ambio has now treated over 3,000 people. Most of what you think you know about ibogaine is probably wrong. It's not a high. It puts you flat on your back for twelve hours and asks for everything. It resets the body off opioids almost overnight. It seems to repair the brain in ways nobody fully understands yet — MS lesions shrinking, a guy walking in with a cane and leaving it behind.  We get into the cardiac risk, the deaths, the Trump executive order, and why the science and the ceremony might not survive being pulled apart. And we talk about the part nobody wants to hear: the medicine doesn't do the work for you. Pick up Jonathan's Book here: https://www.simonandschuster.com/books/Ibogaine-and-the-Bicameral-Mind/Jonathan-Dickinson/9798888504680 Join the Cleared Hot Newsletter: https://www.clearedhotpodcast.com   Today's Sponsors: Black Rifle Coffee: https://www.blackriflecoffee.com LMNT: https://www.drinklmnt.com/clearedhot  

The ancient fruit sitting in your grocery store right now outperforms rapamycin, rivals caloric restriction, and triggers a cellular cleanup process that most longevity scientists did not even know existed until a lab changed everything 18 years ago. -Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR -Go to timeline.com/Dave or just use code ‘Dave' to get 20% off your next order. Host Dave Asprey sits down with Chris Rinsch, co-founder and President of Timeline Longevity and a PhD cell biologist who has spent nearly two decades doing pharmaceutical quality clinical research on one of the most underrated longevity molecules on earth. Before founding Timeline in 2007, Rinsch worked in venture capital investing in pioneering life sciences companies and in biotechnology developing cell-based therapies at Swiss biotech company ISOTIS SA. He has authored original publications in Nature Medicine, Nature Metabolism, JAMA Open, and Cell Reports Medicine, and holds internationally filed and granted patents on urolithin A. This is the first time a Timeline co-founder has appeared on the show. Together, Dave and Chris break down the full science of urolithin A, the postbiotic compound unlocked from pomegranate by gut bacteria, and why it triggers mitophagy to clear out damaged mitochondria and replace them with high-functioning ones. They cover why only 30 to 40 percent of people can produce urolithin A from food alone, how one month of supplementation measurably improved immune cell populations in people aged 50 to 70, and why Dave has stacked this into his daily longevity protocol alongside NAD precursors and nootropics for years. If you are serious about biohacking your mitochondria, extending healthspan, and doing smarter not harder longevity work, this episode delivers the deep science to back it up. You'll Learn: Why urolithin A outperforms rapamycin in worm lifespan studies and rivals caloric restriction at 45 percent life extension How mitophagy works, why it declines with age, and why it is one of the most important anti-aging mechanisms in the body Why eating pomegranates or taking cheap pomegranate extract does not work for most people and what to take instead How one month of MitoPure improved natural killer cells, CD8 T naive cells, and reduced inflammation in adults aged 50 to 70 Why mitochondria are central to metabolism, brain optimization, immune function, cardiovascular health, and skin aging How Timeline's topical urolithin A produced statistically significant reductions in fine lines and wrinkles after eight weeks Why Dave considers this one of the most clinically validated supplements in his longevity stack alongside NAD and fasting protocols How L'Oreal became a Timeline investor after confirming the mitochondrial science was unlike anything in their existing ingredient library What the XPRIZE Healthspan competition is targeting and why Timeline is competing to reverse biological aging by 10 to 20 years Why the future of functional medicine will require a mitochondrial blood test and how close we are to having one Thank you to our sponsors! - EMR-Tek | https://www.emr-tek.com/DAVE and use code DAVE - Calroy | Go to Calroy.com/DAVE for exclusive discounts on Arterosil HP, Vascanox HP and all Calroy products. - Neuronic | Go to www.neuronic.online Code DAVE for $100 off - ENERGYbits | If you want a simpler, smarter way to support your body… this is it. Head to ENERGYbits.com and use code ASPREY for 20% off your order. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights inhealth, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: Chris Rinsch, Timeline Longevity, MitoPure, urolithin A, mitochondria, mitophagy, pomegranate, elagitannins, postbiotic, gut microbiome, longevity, anti-aging, healthspan, biohacking, supplements, human performance, metabolism, mitochondrial health, cellular health, autophagy, natural killer cells, immune health, inflammation, NAD, rapamycin, caloric restriction, muscle endurance, collagen, skin aging, fine lines, wrinkles, topical skincare, L'Oreal, XPRIZE Healthspan, Nature Aging, clinical trials, longevity stack, brain optimization, cardiovascular health, biological age, aging clock, fasting, nootropics, functional medicine, Dave Asprey, polyphenols, microbiome diversity Resources: • Go to timeline.com/Dave or just use code ‘Dave' to get 20% off your next order. • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Trailer 00:37 – Intro 03:57 – Pomegranates 10:03 – Discovering Urolithin A & Mitophagy 20:50 – Science vs. Pomegranate Supplements 25:24 – Topical Skincare Science 26:09 – L'Oreal Partnership & Skin Results 33:38 – 15 Clinical Studies & XPRIZE 43:50 – Nature Aging Immune Study 49:22 – Dosing & Daily Routine 51:29 – Future of Mitochondrial Health See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: XX Dexcom announces some features of it's next generation CGM – the G8. We've been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they're calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It's an interesting space to watch.. btw, analyte is just a medical word for the specific thing you're measuring – the target of the test you're running. we're going to hear that word a lot I think..   Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that's investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack's device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack's active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology.   PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics' CGM.   PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems.   Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX   XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It'll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/--   XX Diabeloop just got CE Mark approval for DBLG2 integrations – it's latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it's integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps "available soon." Running on a user's smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/   XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis.   METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx   XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.   "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease.       https://scitechdaily.com/scientists-just-rewrote-biology-hidden-mechanism-could-transform-diabetes-treatment/ XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes.   The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX   A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. "This study is the tip of the iceberg," said Dr. Evans-Molina. "We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data."   https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.   "This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied," said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center.   Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.   What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report.   The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes.   GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.   "Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings," said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health.   What's next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials.   "Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making," Fuemmeler said. https://www.oncology-central.com/could-glp-1-receptor-agonists-improve-outcomes-for-breast-cancer-patients-with-obesity-or-with-type-2-diabetes/ XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. "We would think that chronic cannabis users would be eating more and weigh more, but it's just the opposite," DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body's endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here's what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes.   One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes

In this episode, I explore where AI can genuinely help with health questions, where it can fall dangerously short, and how to use it more wisely before trusting it with decisions that really matter.AI tools like ChatGPT, Claude, Grok, and Gemini can be useful for understanding lab results, summarizing a doctor's visit, preparing questions before an appointment, or making sense of complicated medical language. But when people ask AI, “What's wrong with me?” or “Should I go to the hospital?” the answer can depend heavily on whether the user provides enough clinical context.I tested this myself with two invented scenarios: hand pain and a concerning headache. In both cases, the AI gave general guidance but failed to ask key questions a physician would naturally ask, such as my age, whether symptoms came on suddenly, whether I had experienced this before, or whether there was relevant family history. When I explicitly asked the AI to interview me first, the answers improved dramatically.Research supports that concern. A recent Nature Medicine study found that when real users interacted with AI about clinical scenarios, the AI gave the correct triage recommendation in only about 43% of cases and often underestimated urgency. The problem was not always that AI lacked medical knowledge. It was that users often did not provide enough information, and the AI did not reliably ask for what it needed.Another Nature Medicine study tested ChatGPT Health using complete clinical vignettes. Even with all the information provided, the AI struggled with the most urgent and least urgent cases. It sometimes recognized serious diagnoses but recommended delayed care when immediate emergency care was appropriate. That suggests the issue is not just knowledge, but judgment.AI does perform better in lower-risk, supportive roles. It can translate medical jargon into plain language, explain abnormal lab results, organize a visit summary, and help patients prepare better questions for their doctor. Recording a medical visit with the doctor's permission and then using AI to create a personal summary can be especially helpful, though AI-generated clinical notes still need careful physician review.The most practical strategy is simple: before asking AI for health guidance, tell it, “Before you respond, please ask me all the questions you need to give me accurate information about my situation.” This does not make AI a doctor, but it can make the interaction more useful and less incomplete.Takeaways: AI can be helpful for understanding, organizing, and preparing for healthcare conversations, especially when the stakes are relatively low. AI is not yet reliable enough to determine whether symptoms are urgent or whether you should go to the ER. When using AI for health questions, ask it to interview you first, and when symptoms feel serious, unusual, sudden, or frightening, do not rely on AI as your final decision-maker.Send us Fan Mail

This week on “Health Talk America presents The Dr. Bob Martin Show”, Dr. Adam Brockman takes youcoast-to-coast through today's most powerful health headlines. From the "Day of Reckoning" for Purdue Pharma and the opioid fallout shaking America's courts, to the FDA's controversial rejection of a promising melanoma therapy, it's a show that pulls no punches. Then, pivoting from policy to physiology, Dr. Brockman dives into the groundbreaking “Nature Medicine” study that's rewriting what we know about women's biology. Discover why “cycle-syncing” isn't a fad but a frontier in human performance, longevity, and healthcare equality. Whether you're in the gym, on the road, or tuning in online at “healthtalkamerica.com”, this episode delivers clarity, controversy, and actionable insight—because knowledge, as always, is the best medicine.Health Headlines of the WeekHealth Alternative of the WeekHealth Outrage of the WeekHealth Mystery of the Week

Most people think their kitchen is the safest place in their home. The truth is the opposite. The cookware you use every day, the cutting boards you trust, the utensils you stir with, even the coffee maker on your counter, may be quietly leaching forever chemicals, microplastics, and heavy metals into your food and into your brain. In this episode, I sit down with Jordan Nathan, founder and CEO of Caraway, the brand redefining what nontoxic actually means in the modern home. Jordan walks me through the night he called poison control after overheating a Teflon pan, the 2-year journey to launch a cookware line free of PFAS, and why six U.S. states have now banned forever chemicals in cookware. We unpack what PFAS, PFOA, and PTFE actually are, why they accumulate in fat tissue and cross the blood brain barrier, and why scratched pans, plastic cutting boards, and black nylon utensils are some of the most dangerous things in your kitchen. Then we go deep on the science. I break down the Nature Medicine 2025 study showing microplastics in human brain tissue at higher concentrations than the liver or kidney, with the highest accumulation found in dementia brains. We cover the rise of autoimmune disease, the credit card's worth of plastic the average person consumes every week, Caraway's third party testing for over 600 PFAS chemicals, and a full kitchen audit on a $1,000 budget covering induction vs gas, dishwasher dangers, and what's coming next as Caraway expands into the broader nontoxic home. This conversation will completely change how you think about what is in your kitchen, what is in your body, and what you can actually do about it. Reduce your risk of Alzheimer's with my science-backed protocol for women 30+: https://go.neuroathletics.com.au/youtube-sales-page Subscribe to The Neuro Experience for evidence-based conversations at the intersection of brain science, longevity, and performance. _____ TOPICS DISCUSSED 00:00 Intro: Plastic Is Hiding in Plain Sight in Your Kitchen 01:36 The Night Jordan Called Poison Control Over a Teflon Pan 05:06 PFAS, PFOA, and PTFE: What Forever Chemicals Actually Are 09:35 Why PFAS Accumulate in Fat Tissue and Cross the Blood Brain Barrier 13:31 The Birth of Caraway and What the Name Actually Means 17:50 Why 6 States Have Banned PFAS in Cookware 19:22 Third Party Testing: How Caraway Tests for 600+ PFAS Chemicals 23:10 The Steve Jobs Mentality: Industry Standards Aren't Our Standards 29:31 Scratched Pans, Plastic Cutting Boards, and the Hidden Risks 33:18 Microplastics Found in Human Brain Tissue: The 2025 Study 37:28 Caraway's Bestsellers and the Expansion Into the Whole Home 40:20 Cast Iron, Stainless Steel, and How to Choose Cookware 41:29 Why You Should Never Put Cookware in the Dishwasher 43:02 Gas vs Induction Stoves: Which One Is Actually Safer 44:30 The Full $1,000 Kitchen Audit: Where to Start 49:21 Black Plastic, Nylon Utensils, and the Truth About Takeout Containers 51:00 One Thing Jordan Wishes He Knew About the Average Kitchen _______ Thank you to our sponsors DailyBasis: https://www.dailybasislife.com/NEURO for 50% off first month JSHealth: https://jshealthvitamins.com and use code NEURO for 20% off BASED Bodyworks: https://basedbodyworks.com/ and use code NEURO for 20% off _______ I'm Louisa Nicola - clinical neurophysiologist - Alzheimer's prevention specialist - founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention. If you're committed to optimizing your brain- reducing Alzheimer's risk - and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0 Instagram: https://www.instagram.com/louisanicola_/ Twitter : https://twitter.com/louisanicola_ Learn more about your ad choices. Visit megaphone.fm/adchoices

Matt Galsky joins the show to talk about duration of EVP in multiple bladder cancer settings. He also talks about his recent Nature Medicine manuscript on the PPARG inverse agonist in advanced bladder cancer.

Dietitian Nutritionist Leyla Muedin discusses a Stanford-led randomized controlled trial published in Nature Medicine in which a five-day, calorie-restricted fasting-mimicking diet improved symptoms and inflammatory markers in people with mild to moderate Crohn's disease. In the three-month study of 97 patients, 65 followed monthly five-day cycles of 700–1100 calories/day with plant-based meals, while 32 continued usual diets; about two-thirds of the fasting-mimicking group reported symptom improvement, with fatigue and headaches but no serious side effects, and fecal calprotectin and other inflammatory molecules decreased. She notes bowel rest and the specific carbohydrate diet as additional approaches. The episode also explains how antibiotics can cause diarrhea by disrupting gut bacteria, lists higher-risk antibiotics, offers supportive steps (hydration, BRAT foods, avoiding irritants), recommends Saccharomyces boulardii taken away from antibiotics, and outlines warning signs requiring medical care, including possible C. difficile.

Send us Fan MailIt's a rare piece of good news. A single-dose dengue vaccine developed in Brazil as part of an international collaboration protected people against at least two strains of the virus for five years or longer, and did so safely. The vaccine was already being tested across Brazil and the findings helped boost confidence in its use. “This is a big deal,” says Dr. Andre Siqueira, Head of the Dengue Global Program at the Drugs for Neglected Diseases Initiative (DNDI).  Dr. Siqueira, who is also an Infectious Diseases Consultant at Brazil's Instituto Nacional de Infectologia Evandro Chagas, a hospital that is part of the Oswaldo Cruz Foundation (Fiocruz), helped develop the vaccine. He chatted with One World, One Health about the work in 2024. The new vaccine worked almost perfectly to keep people from being hospitalized with severe dengue symptoms, Dr. Siqueira and the team reported in Nature Medicine.  That's a big deal. Dengue can cause terrible symptoms, including severe abdominal pain, internal bleeding, severe muscle aches, and long term fatigue. From January 2025 to January 2026, dengue killed more than 4,000 people. The only other dengue vaccines currently available are a two-dose formula made by Japanese manufacturer Takeda and Sanofi's Dengvaxia, which the company is discontinuing because of a lack of demand. In this episode, Siqueira updates host Maggie Fox about the latest findings on the new vaccine's efficacy and its rollout in Brazil. 

A recent study published in Nature Medicine claims a blood test can predict when you'll develop Alzheimer's disease, and it got a lot of attention. But how well does it actually work, and should you rush out and get tested? In this episode, we break down the study behind the headlines to understand what it really shows, where the major limitations lie, and what it means for anyone thinking about getting this kind of test. Topics and Questions Covered What P-Tau 217 is and why it's become the leading blood-based biomarker in Alzheimer's research. How researchers built a predictive "clock" from blood test data and what that process required. The important distinction between having pathology in your brain and actually developing dementia. Who should and should not be getting tested. What a large Norwegian population study reveals about the overlap between pathology and normal cognitive function. How biomarkers like this might eventually fit into a broader, more personalized approach to prevention. and more! -------------- To submit a question for us to answer on the podcast, go to brainjo.academy/question. To subscribe to the free Better Brain Fitness newsletter, join us when we record live, and get our Guide and Checklist to essential blood tests and nutrients, go to: betterbrain.fitness. To learn more about how you can boost brain fitness with neuroscience-based musical instruction, head to brainjo.academy.  Intro and Outro music composed and produced by Julienne Ellen. 

Shahad Abdulsahib discusses a phase 1 clinical trial of intracerebroventricular bivalent EGFR and IL13Rα2 CAR T cells for recurrent glioblastoma, published in Nature Medicine.

A randomized trial in the New England Journal of Medicine found prehospital whole blood transfusion did not improve 30-day mortality over standard component therapy in traumatic hemorrhage, supporting current transfusion protocols. A large population-based study showed patients with positive fecal occult blood tests who did not complete follow-up colonoscopy had significantly higher colorectal cancer incidence and more advanced-stage disease. Finally, a study in Nature Medicine of nearly 15,000 individuals found antibiotic exposure reduced gut microbial diversity for up to 4–8 years, with clindamycin and fluoroquinolones causing the most persistent disruption.

Join us in this episode for a conversation with Aaron Phillips, PhD, scientist and Associate Dean of the Medical School at the University of Calgary. In this conversation we discuss two papers, A neuronal architecture underlying autonomic dysreflexia published in the journal Nature, and An implantable system to restore hemodynamic stability after spinal cord injury published in the journal Nature Medicine. In these papers Dr. Phillips and his team first identify specific neuronal components, and their location, responsible for blood pressure increases due to autonomic dysreflexia. Then an implantable device is demonstrated to help control, via neuromodulation, blood pressure fluctuations in both pre-clinical models and people living with SCI. We invite you to listen in as Dr. Phillips outlines this tour de force in neurologically understanding, and intervening on, hemodynamic instability after SCI.

Join us in this episode for a conversation with Aaron Phillips, PhD, scientist and Associate Dean of the Medical School at the University of Calgary. In this conversation we discuss two papers, A neuronal architecture underlying autonomic dysreflexia published in the journal Nature, and An implantable system to restore hemodynamic stability after spinal cord injury published in the journal Nature Medicine. In these papers Dr. Phillips and his team first identify specific neuronal components, and their location, responsible for blood pressure increases due to autonomic dysreflexia. Then an implantable device is demonstrated to help control, via neuromodulation, blood pressure fluctuations in both pre-clinical models and people living with SCI. We invite you to listen in as Dr. Phillips outlines this tour de force in neurologically understanding, and intervening on, hemodynamic instability after SCI.

Shahad Abdulsahib discusses a phase 1 clinical trial of intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma, published in Nature Medicine in January 2025.

A structural shift is occurring in the managed IT services landscape as AI capabilities are rapidly embedded across enterprise applications, with oversight and risk management functions increasingly separated out and monetized as add-on services. Vendors, including Microsoft and OpenAI, are deploying AI agents in essential tools such as Outlook, Teams, and Excel, then selling governance, security, and compliance capabilities as additional paid layers. The core mechanism is the transfer of operational and liability risk downstream to IT service providers and their clients, while ownership of the control plane and margin on risk mitigation remain with the vendors. The episode highlights consequential findings regarding AI reliability and adoption. A Nature Medicine study found that OpenAI's ChatGPT Health underestimated emergency severity in 51.6% of cases, prompting concerns about overreliance on AI for critical decisions. Additionally, Confluent's UK executive survey indicated that 62% of organizations are already shifting decision-making to AI, but only 7% have a company-wide AI strategy, and fewer than half of executives and employees agree on actual daily AI usage. Most leaders receive little formal AI training yet are second-guessing their own judgment in favor of AI output. Further reinforcing the governance gap, Microsoft is launching Agent 365 and new enterprise security tiers, while OpenAI's acquisition of Promptfoo signals a focus on AI reliability testing and compliance monitoring. Funding for GRC platforms like IntelliGRC demonstrates capital flowing into third-party oversight solutions. The recurring pattern is vendors first pushing broad agent adoption, then introducing and monetizing governance as a discrete add-on, often outside the default package. Operationally, MSPs and IT leaders face increased liability exposure if they rely on vendor-native governance without independent audit or measurement capability. The absence of industry-standard reliability metrics for AI, combined with the perception and usage gaps inside organizations, calls for MSPs to lead in auditing, documenting, and independently measuring AI usage and performance. Failing to proactively manage these controls can result in silent risk absorption and unfavorable positioning as vendors bundle compliance and pass residual risk downstream to service providers. Three things to know today 00:00 AI vs. Judgment                            02:35 Agents vs. Oversight 04:04 AI Reliability Gap 05:15 Why Do We Care?  Supported by:  ScalePad 

This episode critically examines a recent Nature Medicine paper on the timing of immune therapy infusion in lung cancer, exploring the scientific plausibility, methodological concerns, and implications for future research. Tom, Brian and David McDermott debate the validity of the findings, the review process, and the need for rigorous prospective trials.

Psychedelic medicine is moving from the margins to mainstream neuroscience.

About the Guest(s): Dr. Kristin Hieshetter is the host of Functional Health Radio, an established healthcare professional with expertise in functional medicine, chiropractic care, and neuroinflammation. With a rich background in educating medical, chiropractic, and dental professionals, Dr. Kristin is dedicated to translating complex medical research into practical knowledge for both her peers and the general public. She regularly integrates insights from reputable medical journals into her work and travels to share her knowledge at various continuing education events for healthcare providers. Episode Summary: In this engaging episode of Functional Health Radio, Dr. Kristin Hieshetter delves into the implications of COVID-19 as a brain disease, discussing its impact on long-term neurological health and offering insights into potential therapeutic strategies. Highlighting the struggles faced by the 225 million individuals worldwide known as "Covid long haulers," Dr. Kristin shares her expertise on the often debilitating neurological symptoms that persist in many patients well after recovery from the initial infection. Throughout the episode, Dr. Kristin explores the science behind COVID-19's effects on the brain, emphasizing the structural impact of the virus's spike proteins and their lingering presence. By referencing several studies, including those published in top-tier journals such as Molecular Neurobiology and Nature Medicine, she discusses the immune-mediated pathways that lead to neuroinflammation, cognitive deficits, and reduced gray matter in COVID-19 patients. She sheds light on the necessity for personalized protocols when treating long-haul symptoms, combined with the use of low-level lasers, supplements, and lifestyle changes to promote healing and brain health. Key Takeaways: COVID-19 can have long-term neurological effects, leading to symptoms such as brain fog, memory loss, and anxiety. Spike proteins from the virus remain in the body, contributing to neuroinflammation and facilitating long-term cognitive issues. Integral therapeutic approaches include tailored supplementation, regular exercise, low-level laser therapy, and controlled doses of methylene blue. Variability in patient responses necessitates highly individualized treatment plans to manage and potentially reverse symptoms. Maintaining brain health requires attention to exercise, nutrition, and supplementation to combat the inflammatory effects of the virus. Notable Quotes: "Both long Covid and COVID vaccine can sometimes create things like brain fog, neuroinflammation, and long term sequelae." "We have more abnormal than normal brains in the world." "The COVID spike proteins, they hang out at the base of the skull, throughout the skull, in a system called the duromeningeal system." "COVID long haulers have way too much inflammation. Low-level laser can help you with that." "For every nerve that goes from the brain to the stomach, nine go back up." Resources: PubMed: Molecular Neurobiology, July 2021 Journal Article: Cell Host and Microbe, Volume 32, 2024 Dr. Greg Fors - BioSpec Nutritionals: Mito Detox 3 Nature Medicine, Volume 31, 2025 Listeners are encouraged to dive into this informative episode to understand fully the complex nature of COVID-19 as a brain disease and its long-term implications on health. Join Dr. Kristin as she prepares to address these pertinent challenges faced by many today and provides tools for navigating them. Stay tuned for more episodes of Functional Health Radio for continued learning and insight.

What if we could take the guesswork out of cancer treatment—and move from try and hope to test and know? In this episode of Med Tech Gurus, we sit down with Jim Foote, CEO and Founder of First Ascent Biomedical, whose mission began after losing his son to cancer. That experience became the driving force behind Functional Precision Medicine (FPM)—a groundbreaking approach that combines tumor testing, genomics, and AI to rank the most effective drugs for each patient in just ten days Backed by a Nature Medicine study showing an 83% patient benefit rate, First Ascent is proving that personalization saves lives. With automation reducing lab times from hours to minutes and new CLIA-certified labs accelerating access, Jim and his team are reshaping how cancer care is delivered. From building trust with clinicians to leading through loss, Jim shares a powerful story of innovation, resilience, and purpose that every medtech leader can learn from.

This special episode brings together the moments from 2025 that listeners told us had the biggest impact on how they eat, think, and feel. It's been a year full of surprising insights, practical shifts, and ideas that made healthy eating feel a little more doable. From gut health breakthroughs to simple food habits that spark real change, these clips highlight the advice that resonated most - that people returned to, shared, and said genuinely helped them feel better. Whether you're pausing to take stock of the year or simply looking for small ideas to weave into everyday life, this episode offers some science-backed inspiration you can carry forward in your own way. Unwrap the truth about your food

Christmas is a time of celebration, when friends and family gather to enjoy meals together. However, many of us overindulge, which leaves us feeling tired, bloated, and guilty. What actually happens to our bodies when we overeat, drink more, and swap fibre for sugar? And is there a way to enjoy the season's pleasures without starting January full of regret? In this episode, ZOE's Head Nutritionist, Dr Federica Amati, joins Jonathan to explore how festive food traditions shape our health and how to navigate them without guilt or restriction. Dr Federica shares practical suggestions for gut-friendly food swaps, festive traditions worth reviving, and the one ingredient she always includes on her own Christmas table. This episode is full of helpful advice on how to care for your body in a season that often asks us to do the opposite. Unwrap the truth about your food